再次治疗背景下钬激光前列腺剜除术的结局
该回顾性研究比较了2003至2015年间4家学术医院2242例接受钬激光前列腺剜除术的患者,其中360例(16%)为再次治疗。再次治疗组围手术期结局与初次治疗组无差异,但血块潴留和尿道狭窄可能性略高,AUA症状评分虽改善但仍高于初次治疗组。
要点
- 再次治疗组占16%(360/2242),71%因残余尿路症状手术,最常见既往术式为经尿道前列腺电切术(42%)。
- 再次治疗组围手术期手术时间更短、出血更少、标本重量更低、住院时间更短。
- 再次治疗组血块潴留(4.7% vs 1.8%,p=0.01)和尿道狭窄(3.3% vs 1.5%,p=0.043)可能性略高。
核心结论
- 再次治疗背景下钬激光前列腺剜除术的即刻围手术期结局与初次治疗无差异,尽管再次治疗与血块潴留、尿道狭窄可能性增加及AUA症状评分较高相关,但这些微小差异需结合两组总体良好的症状改善来考虑。
研究设计与样本
- 回顾性研究,纳入2003至2015年间4家学术医院共2242例接受钬激光前列腺剜除术的患者,比较再次治疗与初次治疗组的人口学、手术及围手术期结局。
主要发现
- 2242例中360例(16%)接受再次治疗钬激光前列腺剜除术,其中71%因残余尿路症状手术,最常见既往术式为经尿道前列腺电切术(42%),距既往手术平均时间68个月(范围1至444)。
- 两组年龄、前列腺大小、AUA症状评分或平均尿流率无显著差异。
- 再次治疗组手术时间更短、出血更少、标本重量更低、住院时间更短。
- 两组AUA症状评分均改善,但再次治疗组仍较高(6.5 vs 5.0,p<0.001)。
- 再次治疗组血块潴留(4.7% vs 1.8%,p=0.01)和尿道狭窄(3.3% vs 1.5%,p=0.043)可能性略高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Holmium laser enucleation of the prostate can also be applied in the re-treatment setting when other benign prostatic hyperplasia therapies fail. We compared outcomes in men who underwent holmium laser enucleation of the prostate in the primary vs the re-treatment setting. MATERIALS AND METHODS: We retrospectively reviewed the records of 2,242 patients who underwent holmium laser enucleation of the prostate at a total of 4 academic hospitals between 2003 and 2015. Patient demographics, and operative and perioperative outcomes were compared between re-treatment and primary holmium laser enucleation of the prostate. RESULTS: Of the 360 of 2,242 men (16%) who underwent re-treatment holmium laser enucleation of the prostate the procedure was done for residual urinary symptoms in 71%. The most common primary procedure was transurethral resection of the prostate in 42% of cases. Mean time between prior benign prostatic hyperplasia surgery and re-treatment was 68 months (range 1 to 444). There were no significant differences in age, prostate size, AUA (American Urological Association) symptom score or average flow rate between the cohorts. Perioperatively, re-treatment holmium laser enucleation of the prostate was associated with significantly shorter operative time, reduced blood loss, lower specimen weight and shorter length of stay. The AUA symptom score improved in both groups, although it remained higher in men who underwent re-treatment (6.5 vs 5.0, p <0.001). The likelihood of clot retention (4.7% vs 1.8%, p = 0.01) and urethral stricture (3.3% vs 1.5%, p = 0.043) was slightly higher in the re-treatment group. CONCLUSIONS: Immediate perioperative outcomes of holmium laser enucleation of the prostate performed in the re-treatment setting were no different from those in the primary setting. While re-treatment was associated with an increased likelihood of clot retention, urethral stricture and higher AUA symptom score, these minimal differences must be considered against the overall favorable symptom improvement across both cohorts.
引用
- Marien T, Kadihasanoglu M, Tangpaitoon T, et al. Outcomes of Holmium Laser Enucleation of the Prostate in the Re-Treatment Setting. J Urol. 2016. PMID: 28043843. doi:10.1016/j.juro.2016.12.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。